<DOC>
	<DOC>NCT00765804</DOC>
	<brief_summary>The purpose of this study is to assess the safety and efficacy of iontophoretic delivery of dexamethasone phosphate ophthalmic solution using the EyeGateÂ® II Drug Delivery System in patients with dry eye.</brief_summary>
	<brief_title>Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Dry Eye</brief_title>
	<detailed_description>The objective of this study is to assess the safety and efficacy of Ocular Iontophoresis with Dexamethasone Phosphate 40 mg/mL 7.5 mA-min at 2.5 mA and Ocular Iontophoresis with Dexamethasone Phosphate 40 mg/mL 10.5 mA-min at 3.5 mA compared to placebo for the treatment of the signs and symptoms of dry eye.</detailed_description>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Have a reported history of dry eye in each eye Be at least 12 years of age Demonstrate a response when exposed to the Controlled Adverse Environment model Have contraindications to the use of the test articles Have known allergy or sensitivity to the study medication or their components (including corticosteroids) Have any ocular infections, active ocular inflammation or preauricular lymphadenopathy Be current contact lens wearers or wear contacts during the study</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Dry Eye</keyword>
	<keyword>Iontophoresis</keyword>
	<keyword>Ophthalmic Delivery</keyword>
</DOC>